Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590451 | 0.83 | HTR6 (0.67) | HTR6POLBHTR2CCYP1A2CYP3A4 | |
| SCHEMBL1590132 | 0.83 | HTR6 (0.67) | HTR6POLBHTR2CCYP1A2CYP3A4 | |
| SCHEMBL1590546 | 0.79 | HTR6 (0.63) | HTR6HTR2CADRA2A | |
| SCHEMBL12702571 | 0.78 | HTR6 (0.62) | HTR6HTR2CCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL1590238 | 0.78 | HTR6 (0.62) | HTR6HTR2CADRA2A | |
| SCHEMBL1422664 | 0.78 | HTR6 (0.57) | HTR6HTR2CADRA2A | |
| SCHEMBL1590266 | 0.78 | HTR6 (0.66) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1590421 | 0.78 | HTR6 (0.61) | HTR6HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL1590499 | 0.77 | HTR6 (0.63) | HTR6HTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1590414 | 0.77 | HTR6 (0.62) | HTR6HTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324035-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-05-25 | — | — | EP | claimed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | claimed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| WO-2009135927-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR2A, HTR4 | HTR6 1/4885POLB 3975/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.